Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Nabumetone

Catalog No: tcsc2669

Available Sizes

Size: 1g

Size: 5g

Size: 10g

Specifications

CAS No:
42924-53-8

Formula:
$C_{15}H_{16}O_2$

Pathway:
Immunology/Inflammation

Target:
COX

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 100 mg/mL (438.04 mM); H2O :

Alternative Names:
BRL14777

Observed Molecular Weight:
228.29

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective **COX-2** inhibitor, and is the prodrug of the active metabolite 6MNA.

IC50 & Target: COX-2[1]

In Vitro: Nabumetone is a potent and selective COX-2 inhibitor. Nabumetone (50 μmol-2 mmol) dose-dependently inhibits the proliferation of K-562 and Meg-01 cells, but shows no obvious apoptotic effect. Nabumetone potentiates the apoptotic effect of ADR in the K-562 cell line. Moreover, Nabumetone reduces Bcl-2 expression[1].

In Vivo: Nabumetone (79 mg/kg, p.o.) inhibits paw oedema and paw exudate PGE_2 in rats. Nabumetone does not induce gastric damage and causes only 57% inhibition of gastric mucosal 6-keto-$PGF_{1\alpha}$ production in rats[2]. Nabumetone (25, 50, 100 mg/kg, i.p.) dose-dependently inhibits the increase of DDC-induced mucus secretion and stimulates stress-induced mucus secretion in rats. Nabumetone (25 mg/kg, i.p.) significantly suppresses stress-induced ulcer index in rats[3].